A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
about
The proteasome and proteasome inhibitors in multiple myeloma.Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Precision Medicine for Heart Failure: Lessons From Oncology.
P2860
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A retrospective analysis of 39 ...... nhibition in multiple myeloma.
@en
type
label
A retrospective analysis of 39 ...... nhibition in multiple myeloma.
@en
prefLabel
A retrospective analysis of 39 ...... nhibition in multiple myeloma.
@en
P2093
P2860
P50
P356
P1476
A retrospective analysis of 39 ...... inhibition in multiple myeloma
@en
P2093
Avinash Desai
Dixie-Lee Esseltine
Edward A Faber
Edward Dow
Helgi van de Velde
Hongliang Shi
Huaibao Feng
Javid J Moslehi
Jennifer Elliott
Laura Rosiñol
P2860
P304
P356
10.1111/BJH.14708
P407
P50
P577
2017-05-03T00:00:00Z